Allergan Eyes Posurdex In Oculex Buy; Edema Approval Could Come In 2006
Allergan could enter the retinal therapy market in late 2006 with Oculex' macular edema implant Posurdex following its $230 mil. acquisition of the technology company
You may also be interested in...
Allergan expects to launch the ophthalmic antihistamine Elestat (epinastine) during the first quarter of 2004
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011